Core Insights - ONWARD Medical N.V. is set to report its Full-Year 2025 Financial Results and provide a business update on March 31, 2026 [1][2] Company Overview - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement, function, and independence for individuals with spinal cord injuries and other movement disabilities [3] - The company has developed proprietary ARC Therapy, which has received 10 Breakthrough Device Designations from the FDA [3] - The ARC-EX System is commercially available in the US and Europe, while the investigational ARC-IM system is being developed to address unmet needs such as blood pressure instability after spinal cord injury [3] - The company is headquartered in the Netherlands, with additional facilities in Switzerland and the US [4] Future Developments - The ARC-IM system is designed to be paired with brain-computer interfaces (BCI) and artificial intelligence (AI) to facilitate thought-driven movement [3]

Core Insights - Longeviti Neuro Solutions has appointed Robert W. Sharps, CEO of T. Rowe Price Group, to its Board of Directors, indicating a strategic move to enhance governance and growth [1][4][6] Company Overview - Longeviti Neuro Solutions is a neurotechnology company focused on developing advanced implantable and AI-enabled solutions for neurological health, including the ClearFit AI™, the first Acoustic Brain Interface (ABI)™ [1][7] - The company aims to improve the understanding and treatment of neurological conditions while supporting long-term brain health and human performance [4][7] Leadership and Expertise - Robert W. Sharps brings over 30 years of leadership experience in global asset management and corporate governance, overseeing more than $1.5 trillion in assets at T. Rowe Price [2][5] - His appointment is expected to strengthen Longeviti's strategic planning, governance, and partnerships as the company scales its operations [4][6] Product and Technology Development - Longeviti is known for its FDA-cleared products and has full in-house manufacturing capabilities, with over 50 patents worldwide and products approved for use in over 120 hospitals globally [8] - The company has successfully used its neurosurgical implants in more than 4,000 patients, showcasing its impact in the field of neurotechnology [8]

Neurotechnology company Science raised $230 million from investors to commercialize its implant for blindness and develop even more advanced brain devices https://t.co/tNO6XfzQbA ...

Core Insights - OneMedNet Corporation has entered a strategic data licensing agreement with Risorius Co., Ltd., focusing on AI-ready Real-World Data for neurotechnology applications [1][5] - The partnership aims to enhance subscription contracts and generate millions in recurring revenue for OneMedNet [1][5] Group 1: Agreement Details - The agreement was executed rapidly, indicating strong commercial alignment and immediate customer value [2] - Risorius has licensed large-scale EEG and PSG waveform data, which will support R&D and model validation for CNS-related studies [3][4] - The datasets will aid in the development of EEG-based digital biomarkers and an AI Co-Scientist platform [3][9] Group 2: Company Strengths - OneMedNet's data assets are characterized by high fidelity, substantial volume, and a structured curation process, making them attractive for R&D needs [4] - The company’s continuous delivery model and regulatory-grade data are seen as foundational for advancing CNS disorder solutions [5] - OneMedNet's iRWD™ platform taps into over 2,130 healthcare sites, providing diverse data that fuels innovation across various medical fields [6] Group 3: Industry Context - The partnership reflects a growing demand for high-quality datasets from AI-native companies in the neurotechnology sector [5] - Risorius aims to optimize CNS research and care delivery through its AI Co-Scientist platform, which translates EEG data into actionable insights [10]

Core Insights - ONWARD Medical N.V. has initiated the Empower BP study, a pivotal global study to assess the safety and effectiveness of the ARC-IM System for managing blood pressure instability in individuals with chronic spinal cord injury (SCI) [1][2][7] Group 1: Study Overview - Empower BP is the first global pivotal study evaluating the implantable ARC-IM System, involving approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada, France, Germany, Spain, and the UK [2][7] - The study targets individuals with spinal cord injuries at levels C2-T6 and severities of AIS A-D, with the first participant enrolled at Craig Hospital in Denver, Colorado [2][7] Group 2: Clinical Significance - The ARC-IM System aims to address unmet needs after SCI, particularly symptomatic blood pressure instability, which affects 78% of individuals with tetraplegia, yet only 28% receive treatment [3][4] - Chronic low blood pressure can threaten neurological recovery and negatively impact cardiovascular health, leading to symptoms such as dizziness, lightheadedness, and fatigue [3][4] Group 3: Previous Research Findings - Clinical feasibility results published in Nature Medicine indicated that participants receiving ARC-IM Therapy experienced immediate increases in blood pressure and reduced hypotensive symptoms, leading to improved quality of life and greater engagement in rehabilitation activities [4][6] - Benefits included reduced fatigue, improved bowel management, and increased tolerance of upright postures, with participants able to reduce or discontinue traditional low blood pressure treatments [4][6] Group 4: Company Background - ONWARD Medical is a leading neurotechnology company focused on restoring movement, function, and independence for individuals with spinal cord injuries and other movement disabilities, having received 10 Breakthrough Device Designations from the FDA [6][9] - The company is headquartered in the Netherlands, with additional facilities in Switzerland and the US, and is publicly listed on Euronext and OTCQX [9]

Core Insights - ONWARD Medical N.V. has appointed Ali Kiboro as Chief Financial Officer effective January 2026, bringing over 25 years of financial leadership experience in the medical technology sector [1][2][3] Company Overview - ONWARD Medical is a neurotechnology company focused on spinal cord stimulation therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries and other movement disabilities [4][5] - The company has developed proprietary ARC Therapy and has received 10 Breakthrough Device Designations from the FDA, with its ARC EX System cleared for commercial sale in the US and Europe [4] - ONWARD is also working on an investigational implantable system called ARC-IM, which addresses unmet needs such as blood pressure instability after spinal cord injury and can integrate with brain-computer interfaces and artificial intelligence [4] Leadership and Strategy - CEO Dave Marver expressed confidence in Ali Kiboro's ability to drive growth and scale within the life sciences sector, highlighting the importance of Kiboro's experience at this critical stage for ONWARD [3] - Ali Kiboro holds an MBA in Finance from The Wharton School and a Bachelor of Science in Finance, summa cum laude, from Duquesne University, indicating a strong educational background in finance [3]

Core Insights - ONWARD Medical N.V. successfully raised EUR 50.85 million through an accelerated bookbuild offering, issuing 11.3 million new ordinary shares at an issue price of EUR 4.50 per share [1][2][3] Group 1: Financial Details - The private placement was supported by existing and new investors, including Ottobock SE & Co. KGaA as a cornerstone investor and healthcare specialist investor Invus [2][6] - The net proceeds from the private placement are expected to provide cash runway through at least the end of 2026, assuming no drawdown of the company's debt facility [4][6] Group 2: Use of Proceeds - The company plans to allocate the net proceeds as follows: 40% for development initiatives including product development and clinical studies for the investigational ARC-IM® System, 30% to expand sales and operations for the ARC-EX® System, 20% to support quality and administrative activities, 5% for working capital, and 5% to cover financing costs [7] Group 3: Market Position and Future Plans - ONWARD Medical is transitioning to a commercial-stage company, validated by strong demand for its ARC-EX® System, and plans to use the raised capital to expand commercial activities and advance its pipeline [3][10] - The new shares are expected to be listed on Euronext Brussels, Euronext Amsterdam, and Euronext Paris on October 28, 2025 [8]

Core Viewpoint - ONWARD Medical N.V. is launching a capital increase through a private placement aimed at raising approximately EUR 50 million to support its operations and development initiatives in neurotechnology for spinal cord injuries and movement disabilities [1][2]. Summary by Sections Private Placement Overview - The private placement will involve the issuance of new ordinary shares with a nominal value of EUR 0.12 each, offered to qualified institutional investors [1][3]. - The final number of shares and the issue price will be determined through a bookbuilding process, which is expected to last one business day [4][5]. Use of Proceeds - The net proceeds from the private placement will be allocated as follows: - 40% for product development, clinical studies, and regulatory activities for the ARC-IM System - 30% to expand sales and operations for the ARC-EX System - 20% to support quality and administrative activities - 5% for working capital and general corporate purposes - 5% to cover financing costs, including existing debt obligations [2][6]. Trading and Regulatory Aspects - Trading of ONWARD Medical's shares will be temporarily suspended on Euronext Brussels, Amsterdam, and Paris during the bookbuilding period to facilitate broader investor participation [5][7]. - The new shares are expected to be listed and admitted to trading on October 28, 2025, with payment and delivery occurring on the same day [9]. Company Background - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and independence in individuals with spinal cord injuries and other movement disabilities [11]. - The company has developed the ARC Therapy and has received multiple Breakthrough Device Designations from the FDA for its products [11].

Core Insights - Elon Musk, a serial entrepreneur, has a net worth of $485.5 billion as of October 13, according to Forbes [1] Company Summaries - **Zip2**: Founded in 1995 with $28,000 from Musk's father, Zip2 generated online city guides and was sold to Compaq for $307 million in 1999, netting Musk $22 million [3] - **PayPal**: Musk co-founded X.com with Zip2 profits, which merged with Confinity to become PayPal. eBay acquired PayPal in 2002 for $1.5 billion in stock, resulting in Musk receiving $165 million [4] - **SpaceX**: Founded in 2002, SpaceX has completed 555 space missions and is valued at $400 billion, with Starlink as a subsidiary providing global high-speed internet [5] - **Tesla**: Co-founded in 2003, Tesla went public in 2010 at $17 per share, which has risen to $435.90 per share as of October 13 [6] - **Neuralink**: Established in 2016, Neuralink focuses on brain-computer interfaces for individuals with disabilities and was valued at $9 billion in May 2025 [7] - **The Boring Company**: Founded in 2017, this civil engineering firm has completed projects including the Las Vegas Convention Center Loop, a 1.7-mile transport system [8]

Core Insights - ONWARD Medical N.V. is recognized as a leading neurotechnology company focused on therapies to restore movement and function in individuals with spinal cord injuries and other movement disabilities [1][3] - BNP Paribas' broker Portzamparc has initiated coverage of ONWARD Medical with a Buy rating and a target price of EUR 10.20, indicating strong analyst confidence in the company's growth prospects [1][2] Company Developments - The ARC-EX System has received clearance for commercial use in both the U.S. and Europe, marking a significant transition for ONWARD into a commercial-stage company [2][3] - The company is preparing to initiate a global pivotal study for its investigational implantable ARC-IM platform, which aims to address unmet needs such as blood pressure instability following spinal cord injury [2][3] Market Position - The initiation report from Portzamparc expands ONWARD's equity research coverage to five leading banks, all maintaining a Buy rating and target prices significantly above current trading levels [2] - ONWARD Medical has been awarded 10 Breakthrough Device designations from the FDA, highlighting its innovative approach and regulatory recognition [3] Product Information - The ARC-EX System is designed to deliver programmed, transcutaneous electrical spinal cord stimulation to improve hand sensation and strength in individuals aged 18 to 75 with chronic, non-progressive neurological deficits due to incomplete spinal cord injuries [8] - Other investigational products, including ARC-IM and ARC-BCI, are currently not available for commercial use [9] Company Structure - ONWARD Medical is headquartered in the Netherlands, with additional facilities in Switzerland and a U.S. office in Boston, Massachusetts [4] - The company is publicly listed on Euronext Paris, Brussels, and Amsterdam, with its U.S. ADRs traded on OTCQX [4]